Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$2.16 USD
-0.06 (-2.70%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
AMLX 2.16 -0.06(-2.70%)
Will AMLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AMLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMLX
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
AMLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Other News for AMLX
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
Largest borrow rate increases among liquid names
Cautious Optimism Amidst Uncertainty: Assessing Amylyx Pharmaceuticals’ Future Prospects
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer?s Disease Pathology and Neurodegeneration